Veeva Systems Q1 EPS Forecast Increased by Zacks Research

Veeva Systems Inc. (NYSE:VEEV) – Equities researchers at Zacks Research raised their Q1 2026 earnings estimates for shares of Veeva Systems in a research report issued to clients and investors on Wednesday, March 26th. Zacks Research analyst R. Department now anticipates that the technology company will earn $1.21 per share for the quarter, up from their previous forecast of $1.08. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ FY2026 earnings at $5.07 EPS, Q3 2027 earnings at $1.42 EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at $5.53 EPS and FY2028 earnings at $6.79 EPS.

Several other research analysts have also recently commented on VEEV. Stephens reaffirmed an “overweight” rating and issued a $280.00 target price on shares of Veeva Systems in a research report on Thursday, March 6th. Robert W. Baird increased their target price on Veeva Systems from $283.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, March 6th. Morgan Stanley upped their price target on Veeva Systems from $195.00 to $201.00 and gave the company an “underweight” rating in a research report on Thursday, March 6th. Citigroup lifted their price objective on Veeva Systems from $281.00 to $307.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Needham & Company LLC reissued a “buy” rating and set a $270.00 price target on shares of Veeva Systems in a report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Veeva Systems currently has an average rating of “Moderate Buy” and a consensus price target of $256.52.

Veeva Systems Stock Down 1.4 %

Veeva Systems stock opened at $234.10 on Monday. Veeva Systems has a 12 month low of $170.25 and a 12 month high of $258.93. The stock has a market cap of $38.01 billion, a price-to-earnings ratio of 57.80, a price-to-earnings-growth ratio of 1.89 and a beta of 0.88. The business has a 50 day moving average price of $231.62 and a two-hundred day moving average price of $222.87.

Hedge Funds Weigh In On Veeva Systems

Several hedge funds have recently modified their holdings of VEEV. Principal Financial Group Inc. lifted its holdings in Veeva Systems by 138.9% during the 3rd quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock valued at $457,366,000 after purchasing an additional 1,267,061 shares during the last quarter. Algert Global LLC grew its stake in Veeva Systems by 64.0% in the 3rd quarter. Algert Global LLC now owns 2,254 shares of the technology company’s stock valued at $473,000 after buying an additional 880 shares during the last quarter. D.A. Davidson & CO. grew its position in shares of Veeva Systems by 2.5% in the third quarter. D.A. Davidson & CO. now owns 5,630 shares of the technology company’s stock valued at $1,182,000 after purchasing an additional 136 shares during the last quarter. Townsquare Capital LLC increased its stake in shares of Veeva Systems by 35.7% during the third quarter. Townsquare Capital LLC now owns 4,762 shares of the technology company’s stock worth $999,000 after purchasing an additional 1,253 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Veeva Systems by 17.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 77,653 shares of the technology company’s stock worth $16,297,000 after purchasing an additional 11,433 shares during the last quarter. Institutional investors own 88.20% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.